Peptide Association
Start Your Consultation
All peptides
OncologyFDA Approved

Relugolix (Orgovyx)

Oral
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

Relugolix is an orally bioavailable non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist. Although it is not a peptide, it exerts its therapeutic effect through the same mechanism as peptide GnRH antagonists, competitively blocking pituitary GnRH receptors to suppress gonadotropin and sex steroid production.

Mechanism of Action

It is indicated for advanced prostate cancer and, in combination formulation, for management of heavy menstrual bleeding associated with uterine fibroids and moderate to severe endometriosis pain. The oral route of administration offers a distinct advantage over depot peptide formulations.

Research Summary & Key Findings

Relugolix received FDA approval in 2020 for advanced prostate cancer based on the HERO trial (NEJM 2020), which demonstrated sustained castration in 96.7% of patients compared to 88.8% on leuprolide, with a significantly lower risk of major adverse cardiovascular events. In 2021, a combination product (relugolix with estradiol and norethindrone) was approved for uterine fibroids based on phase 3 trials showing reduction in menstrual blood loss. The rapid reversibility of suppression upon discontinuation is a distinguishing pharmacological feature.

Clinical Status

FDA Approved

Relugolix (Orgovyx) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Oral

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Oncology

Carfilzomib (Kyprolis)

FDA Approved

A tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S...

View details

Bortezomib (Velcade)

FDA Approved

A modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortez...

View details

Lutetium-177 dotatate (Lutathera)

FDA Approved

A radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioiso...

View details

Leuprolide (Lupron) - Oncology

FDA Approved

A GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in pre...

View details

Start Your Consultation

Get an AI-proposed Relugolix (Orgovyx) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Relugolix (Orgovyx).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.